Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert W Baker

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Journal of Clinical Psychopharmacology|August 16, 2003
Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitationRobert W Baker, Bruce J Kinon, Gerald A Maguire, et al.
Journal of Affective Disorders|March 28, 2006
Clinical relevance of depressive symptom improvement in bipolar I depressed patientsDoug Williamson, Eileen Brown, Roy H Perlis, et al.
Chemical Communications (Cambridge, England)|October 4, 2023
Significant cell uptake of Gd(III)-diphenylphosphoryl-diphenylphosphonium complexes: evidence for a new conformationally-dependent tumour cell targeting vectorAndrew J Hall, Amy G Robertson, Robert W Baker, et al.
Clinical Therapeutics|March 5, 2004
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trialLizheng Shi, Madhav A Namjoshi, Ralph Swindle, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 13, 2006
Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trialsJoseph L Micca, Vicki Poole Hoffmann, Ilya Lipkovich, et al.
Bipolar Disorders|June 6, 2002
The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute maniaRobert W Baker, Joseph F Goldberg, Maurico Tohen, et al.
Scientific Reports|May 11, 2018
Salivary levels of total huntingtin are elevated in Huntington's disease patientsJody Corey-Bloom, Ameera S Haque, Sungmee Park, et al.
Journal of Psychiatric Research|October 21, 2005
Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithiumJohn P Houston, Ilya A Lipkovich, Jonna Ahl, et al.
Current Medical Research and Opinion|May 19, 2005
Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trialBaojin Zhu, Sandra L Tunis, Zhongyun Zhao, et al.
Schizophrenia Bulletin|December 25, 2007
Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophreniaHaya Ascher-Svanum, Allen W Nyhuis, Douglas E Faries, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Journal of Clinical Psychopharmacology|August 16, 2003
Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitationRobert W Baker, Bruce J Kinon, Gerald A Maguire, et al.
Journal of Affective Disorders|March 28, 2006
Clinical relevance of depressive symptom improvement in bipolar I depressed patientsDoug Williamson, Eileen Brown, Roy H Perlis, et al.
Chemical Communications (Cambridge, England)|October 4, 2023
Significant cell uptake of Gd(III)-diphenylphosphoryl-diphenylphosphonium complexes: evidence for a new conformationally-dependent tumour cell targeting vectorAndrew J Hall, Amy G Robertson, Robert W Baker, et al.
Clinical Therapeutics|March 5, 2004
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trialLizheng Shi, Madhav A Namjoshi, Ralph Swindle, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 13, 2006
Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trialsJoseph L Micca, Vicki Poole Hoffmann, Ilya Lipkovich, et al.
Bipolar Disorders|June 6, 2002
The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute maniaRobert W Baker, Joseph F Goldberg, Maurico Tohen, et al.
Scientific Reports|May 11, 2018
Salivary levels of total huntingtin are elevated in Huntington's disease patientsJody Corey-Bloom, Ameera S Haque, Sungmee Park, et al.
Journal of Psychiatric Research|October 21, 2005
Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithiumJohn P Houston, Ilya A Lipkovich, Jonna Ahl, et al.
Current Medical Research and Opinion|May 19, 2005
Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trialBaojin Zhu, Sandra L Tunis, Zhongyun Zhao, et al.
Schizophrenia Bulletin|December 25, 2007
Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophreniaHaya Ascher-Svanum, Allen W Nyhuis, Douglas E Faries, et al.
Pageof 4